ACTONEL Drug Patent Profile

When do Actonel patents expire, and when can generic versions of Actonel launch?

Actonel is a drug marketed by Apil and Warner Chilcott and is included in two NDAs.

The generic ingredient in ACTONEL is calcium carbonate; risedronate sodium. There are two hundred and eighty-two drug master file entries for this compound. Additional details are available on the calcium carbonate; risedronate sodium profile page.

Summary for ACTONEL

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	70
Clinical Trials:	35
Patent Applications:	2,791
Drug Prices:	Drug price information for ACTONEL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ACTONEL
What excipients (inactive ingredients) are in ACTONEL?	ACTONEL excipients list
DailyMed Link:	ACTONEL at DailyMed

See drug prices for ACTONEL

See drug sales revenues for ACTONEL

Recent Clinical Trials for ACTONEL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Dong-A ST Co., Ltd.	Phase 4
Wake Forest University Health Sciences	Phase 3
Hospital for Special Surgery, New York	Phase 4

See all ACTONEL clinical trials

Pharmacology for ACTONEL

Drug Class

Bisphosphonate

Paragraph IV (Patent) Challenges for ACTONEL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ACTONEL	Tablets	risedronate sodium	150 mg	020835	1	2008-08-12
ACTONEL	Tablets	risedronate sodium	75 mg	020835	1	2007-09-07
ACTONEL	Tablets	risedronate sodium	5 mg, 30 mg and 35 mg	020835	1	2004-04-23

US Patents and Regulatory Information for ACTONEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-002	Apr 14, 2000		DISCN	Yes	No
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-004	Apr 16, 2007		DISCN	Yes	No
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-001	Mar 27, 1998		DISCN	Yes	No
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-003	May 25, 2002	AB	RX	Yes	Yes
Warner Chilcott	ACTONEL WITH CALCIUM (COPACKAGED)	calcium carbonate; risedronate sodium	TABLET;ORAL	021823-001	Aug 12, 2005		DISCN	Yes	No
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-005	Apr 22, 2008	AB	RX	Yes	Yes

Expired US Patents for ACTONEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-003	May 25, 2002
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-005	Apr 22, 2008
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-003	May 25, 2002
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-002	Apr 14, 2000
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-001	Mar 27, 1998
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-003	May 25, 2002
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-005	Apr 22, 2008

International Patents for ACTONEL

See the table below for patents covering ACTONEL around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2009132709	BISPHOSPHONIC ACID FOR TREATING AND PREVENTING OSTEOPOROSIS
Malaysia	146809	TREATMENT AND PREVENTION OF OSTEOPOROSIS
Australia	8493698
Argentina	027158	FORMA DE DOSIFICACION ORAL PARA SER SUMINISTRADA AL ESTOMAGO, DICHA FORMA DE DOSIFICACION COMPRENDE UNA CANTIDAD SEGURA Y EFECTIVA DE UN INGREDIENTE ACTIVO Y EXCIPIENTES FARMACOLOGICAMENTE ACEPTABLES
Australia	661080
Ireland	853286
Israel	141218

Supplementary Protection Certificates for ACTONEL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1175904	PA2007007	Lithuania		PRODUCT NAME: ACIDUM ALENDRONICUM NATRIUM, COLECALCIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001 2005 08 24 EU/1/05/310/002 2005 08 24 EU/1/05/310/003 2005 08 24 EU/1/05/310/004 2005 08 24 EU/1/05/310/00 20050824
0186405	SPC/GB00/021	United Kingdom		PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
1175904	2007C/048	Belgium		PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826
1175904	CA 2007 00045	Denmark		PRODUCT NAME: ALENDRONSYRE, NATRIUMTRIHYDRAT, OG COLECALCIFEROL
1175904	91364	Luxembourg		91364, EXPIRES: 20200826
0998292	CA 2006 00005	Denmark		PRODUCT NAME: ALENDRONSYRE, NATRIUMTRIHYDRAT, COLECALCIFEROL
1175904	C300292	Netherlands		PRODUCT NAME: ALENDRONINE ZUUR, BIJ VOORKEUR MET MONONATRIUMZOUT IN HET BIJZONDER HET MONONATRIUM TRIHYDRAATZOUT, EN COLECALCIFEROL, WAARIN 70MG ALENDRONINEZUUR AANWEZIG IS, GEBASSERD OP HET GEWICHT VAN ALENDRONINE; REGISTRATION NO/DATE: EU/1/05/310/001-005 20050824

ACTONEL: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Current Market Position and Therapeutic Indication

Actonel (risedronate sodium) is a bisphosphonate medication primarily prescribed for the treatment and prevention of osteoporosis. Its therapeutic indications include postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, and Paget's disease of bone. The drug functions by inhibiting osteoclast activity, thereby reducing bone resorption and increasing bone mineral density.

Actonel is available in various formulations, including oral tablets and a once-monthly oral formulation designed to improve patient adherence. Generic versions of Actonel have been available since 2010, following the expiration of key patents. This has significantly impacted its market exclusivity and pricing dynamics.

Key Competitors and Market Share

The osteoporosis treatment market is competitive, with several established bisphosphonates and newer drug classes vying for market share. Key competitors to Actonel include:

• Fosamax (alendronate sodium): Another widely prescribed oral bisphosphonate.
• Reclast (zoledronic acid): An intravenous bisphosphonate administered annually.
• Boniva (ibandronate sodium): Available in oral and intravenous formulations.
• Prolia (denosumab): A monoclonal antibody that targets RANK ligand, offering a different mechanism of action.
• Evenity (romosozumab): A sclerostin inhibitor approved for women with osteoporosis at high risk of fracture.

The market share for Actonel has been subject to erosion due to the introduction of generic alternatives and the emergence of therapies with different administration profiles or improved efficacy in specific patient populations. While precise, up-to-the-minute market share data for Actonel specifically is proprietary, its overall segment within the bisphosphonate market has faced increased pressure from both generic bisphosphonates and novel anabolic agents.

Patent Landscape and Exclusivity Periods

The patent landscape for Actonel has been critical to its commercial lifecycle. The original patents for risedronate sodium and its therapeutic uses have expired, allowing for generic competition.

• Composition of Matter Patent: Original patents covering the risedronate molecule have long expired.
• Formulation Patents: Patents related to specific formulations, such as the once-monthly tablet, have also expired.
• Method of Use Patents: Patents claiming specific treatment regimens have also seen their exclusivity periods conclude.

The loss of patent exclusivity has led to significant price reductions as generic manufacturers entered the market. This is a standard trajectory for pharmaceutical products once primary patent protection lapses.

Financial Performance and Sales Trajectory

Historically, Actonel generated substantial revenue for its developers and marketers, including Sanofi-Aventis (now Sanofi) and Procter & Gamble. The drug reached blockbuster status, with annual sales exceeding $1 billion.

Sales Performance Trends:

• Peak Sales: Actonel achieved peak annual sales in the mid-to-late 2000s, prior to widespread generic entry.
• Post-Genericization Decline: Following the introduction of generic risedronate sodium around 2010, Actonel's branded sales experienced a sharp and continuous decline. This is a predictable outcome of generic competition, where authorized generics and unbranded generics capture a significant portion of the market at lower price points.
• Current Sales: While specific current sales figures for branded Actonel are not publicly broken out by many companies due to its mature and genericized status, its overall contribution to Sanofi's portfolio has diminished considerably. Generic risedronate sodium, however, continues to represent a significant volume of prescriptions within the osteoporosis market.

Factors Influencing Financial Trajectory:

• Generic Entry: The primary driver of the sales decline for branded Actonel.
• Competition: The introduction of new therapeutic classes (e.g., Prolia, Evenity) offering alternative treatment paradigms.
• Pricing Pressures: Increased negotiation power for payers and pharmacy benefit managers in the face of generic availability.
• Market Saturation: The established use of bisphosphonates in osteoporosis treatment.

Regulatory Environment and Safety Profile

Actonel is approved by regulatory agencies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key Regulatory Considerations:

• Black Box Warnings: Like other bisphosphonates, Actonel carries warnings regarding serious side effects, including osteonecrosis of the jaw (ONJ) and atypical femur fractures. These warnings have been subject to updates and reviews by regulatory bodies over time, influencing prescribing patterns and physician caution.
• Post-Marketing Surveillance: Ongoing pharmacovigilance activities monitor the long-term safety and efficacy of Actonel in real-world patient populations.
• Labeling Changes: Regulatory agencies have mandated labeling updates to reflect emerging safety data, particularly concerning the duration of treatment and the risk of adverse events.

Safety Profile Summary:

The safety profile of Actonel is well-characterized, with common side effects including gastrointestinal upset, musculoskeletal pain, and headache. The serious, though rare, adverse events (ONJ, atypical femur fractures, esophageal irritation) have been a significant focus for regulatory scrutiny and physician education. These safety concerns, alongside the availability of alternatives, have contributed to a more nuanced approach to its long-term use.

Market Trends and Future Outlook

The market for osteoporosis treatments is evolving, driven by advancements in understanding bone metabolism, patient preferences, and the development of novel therapeutic agents.

Current Market Trends:

• Shift to Anabolic Agents: A growing trend towards anabolic agents (e.g., teriparatide, abaloparatide, romosozumab) for patients with severe osteoporosis or those who do not respond adequately to antiresorptive therapies like bisphosphonates.
• Focus on Fracture Prevention: Increased emphasis on reducing fracture risk, particularly in high-risk individuals, leading to the adoption of more aggressive treatment strategies.
• Patient Adherence and Convenience: A demand for treatments with improved convenience and adherence profiles, such as long-acting injectables and less frequent oral dosing.
• Personalized Medicine: Emerging interest in tailoring osteoporosis treatment based on individual patient risk factors, bone turnover markers, and genetic predispositions.

Future Outlook for Actonel (and Risedronate Sodium):

• Continued Generic Dominance: Branded Actonel will continue to see minimal market share. Generic risedronate sodium will remain a significant treatment option, particularly for cost-conscious healthcare systems and patients. Its established efficacy, affordability, and long history of use ensure its place in the therapeutic armamentarium.
• Niche Use Cases: Generic risedronate sodium may find continued use in specific patient populations or healthcare settings where cost is a primary determinant and the risk-benefit profile of bisphosphonates is considered appropriate.
• Competition from Newer Agents: The growth of anabolic agents and monoclonal antibodies will likely continue to constrain the overall market share growth for older antiresorptive therapies.
• Limited R&D Investment: Due to its genericized status, significant new research and development investment specifically for Actonel is unlikely. Focus will remain on optimizing generic manufacturing and distribution.

The long-term trajectory of Actonel as a branded product is one of market maturity and decline. Its legacy, however, is sustained through the continued availability and use of its generic equivalent, risedronate sodium, which remains a cost-effective and viable option for osteoporosis management.

Key Takeaways

Actonel's market trajectory demonstrates a typical lifecycle for a patented pharmaceutical, characterized by initial growth fueled by exclusivity, followed by a significant decline post-patent expiration due to generic competition. While branded Actonel has largely ceded market share, generic risedronate sodium remains a relevant and widely prescribed treatment for osteoporosis due to its established efficacy and affordability. The evolving osteoporosis treatment landscape, marked by the rise of anabolic agents and a focus on fracture prevention, will continue to influence the market dynamics, positioning generic risedronate sodium as a cost-effective option within a more competitive therapeutic environment.

Frequently Asked Questions

1. What is the primary mechanism of action for Actonel? Actonel, a bisphosphonate, inhibits osteoclast activity, thereby reducing bone resorption and increasing bone mineral density.

2. When did generic versions of Actonel become available? Generic versions of Actonel became available in the United States around 2010.

3. What are the major safety concerns associated with Actonel and similar bisphosphonates? Major safety concerns include osteonecrosis of the jaw (ONJ) and atypical femur fractures.

4. How has the introduction of anabolic agents affected the market for bisphosphonates like Actonel? Anabolic agents offer an alternative mechanism of action and are often used for more severe osteoporosis or treatment-resistant cases, leading to increased competition for bisphosphonates.

5. What is the future market outlook for branded Actonel? The market outlook for branded Actonel is characterized by continued decline due to genericization, with its legacy primarily carried forward by generic risedronate sodium.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drug Approval Packages. Retrieved from [FDA Website] (Specific approval dates and documents for Actonel would be accessed here). [2] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from [EMA Website] (Specific assessment reports for risedronate would be accessed here). [3] Sanofi. (Annual Reports, Investor Relations). (Specific financial reports for Sanofi, detailing product sales historically, would be referenced). [4] Various Pharmaceutical Market Research Reports. (Proprietary reports from firms like IQVIA, EvaluatePharma, etc., would contain market share and sales data for osteoporosis drugs). [5] Clinical trial data and publications regarding risedronate sodium. (e.g., Published studies in journals like The New England Journal of Medicine, JAMA).